Miruna Dragomir

Miruna Dragomir

Auto-generated profile, based on publicly available information

Miruna Dragomir

International Prevention Research Institute (IPRI), Lyon, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
PAPhilippe Autier
Philippe Autier
PMPatrick Mullie
Patrick Mullie
AMAlina Macacu
Alina Macacu
MDMiruna Dragomir
Miruna Dragomir
MBMagali Boniol
Magali Boniol
MBMathieu Boniol
Mathieu Boniol

24 August 2017 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
MBMathieu Boniol
Mathieu Boniol
MDMiruna Dragomir
Miruna Dragomir
PAPhilippe Autier
Philippe Autier
PBPeter Boyle
Peter Boyle

15 September 2015 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
PSPhilippe Saiag
Philippe Saiag
PAPhilippe AEGERTER
Philippe AEGERTER
DVDominique Vitoux
Dominique Vitoux
CLCeleste Lebbé
Celeste Lebbé
PWPierre Wolkenstein
Pierre Wolkenstein
MBMathieu Boniol
Mathieu Boniol
A low 25-hydroxyvitamin D3 (25(OH)D3) serum concentration at melanoma diagnosis might be associated with worse survival. We prospectively studied the prognostic value of 25(OH)D3 at diagnosis and during follow-up. MelanCohort is a cohort of invasive melanoma patients. Serum 25(OH)D3 was measured by mass spectrometry and standardized on month of blood drawn, age, sex, and body mass index (BMI). Role of 25(OH)D3 levels and risk of relapse was analyzed in a Cox proportional hazards model adjusting for age, sex, BMI, and American Joint Committee on Cancer (AJCC) stage. All statistical tests were two-sided. One thousand one hundred seventy-one patients were included. 25(OH)D3 levels at diagnosis (median = 49.0 nmol/L) were inversely correlated with prognostic factors such as AJCC stage (P < .001 Kruskal-Wallis), Breslow’s thickness (P < .001 Spearman correlation), and ulceration (P < .001 Kruskal-Wallis), but not with risk of relapse. Changes in 25(OH)D3 levels during follow-up were associated with worse prognosis: With a third quartile Q3 of average change per year (-0.30 to 4.60 nmol/L/Y) used as reference, hazard ratios for the first, second, and fourth quarters were 1.94 (95% confidence interval [CI] = 1.36 to 2.76), 1.23 (95% CI = 0.85 to 1.78), and 1.61 (95% CI = 1.14 to 2.28), respectively. In sensitivity analyses, no changes were observed either by AJCC stage, number of 25(OH)D3 measures performed, or by 25(OH)D3 level at baseline. No evidence of reverse causation was identified. Analyses performed on overall survival yielded similar results. We show that 25(OH)D3 variation during follow-up is an independent melanoma prognostic marker, but not its level at diagnosis. Previously reported associations between low 25(OH)D3 level at diagnosis and poor prognosis seem to be due to insufficient adjustment for prognostic factors.

1 January 2020 in Journal of Health Inequalities
Verified
Journal Article
Open access
MDMiruna Dragomir
Miruna Dragomir
CPCécile Pizot
Cécile Pizot
AMAlina Macacu
Alina Macacu
AKAlice Koechlin
Alice Koechlin
MBMaria Bota
Maria Bota
PBPeter Boyle
Peter Boyle
Objectives This article aims to provide a comprehensive overview of the worldwide burden of prostate cancer by exploring its global incidence, mortality, and survival. Material and methods Incidence rates were extracted from the CI5plus and NORDCAN databases. Prostate cancer deaths and...

1 October 2026 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
CACaroline Apra
Caroline Apra
EPElliot Palfi
Elliot Palfi
EAEmma Afri
Emma Afri
ETEstelle Villedieu de Torcy
Estelle Villedieu de Torcy
MDMiruna Dragomir
Miruna Dragomir
SPStéphane Palfi
Stéphane Palfi
Purpose: Cancer surgery remains a cornerstone of oncologic care, with nearly half of all patients with cancer undergoing resection as their initial treatment. In France, where over 480,000 newly diagnosed patients with cancer are diagnosed annually, this translates to approximately 220,000 surgical procedures each year—a figure reflective of global trends and projected to rise. Reoperation, whether due to residual disease or recurrence, poses a significant clinical and economic burden, yet its incidence and impact remain understudied. Materials and Methods: This retrospective analysis leverages the French Medicalized Information System Program database to examine reoperation rates across five cancer specialties—breast, urogenital, digestive, skin, and neurologic—over a 5-year period (2019-2023). Results: Among 706,495 patients who underwent primary cancer resection, 4.8% required early reoperation for local recurrence: 6.5% for skin, 4.2% for neurologic, 4.0% for breast, 3.7% for urogenital, and 3.5% for digestive cancers. Late reoperation rates were highest in digestive (27.9%) and urogenital (24.1%) cancers, followed by skin (19.7%), breast (18.7%), and neurologic (12.8%) cancers. Reoperation significantly extended hospital stays, and costs were significantly higher, particularly for digestive cancers, where reoperation costs averaged €4,800 compared with €1,500 for primary surgeries. Conclusion: The study's data set, covering 68 million patients, ensures robust representation of France's cancer surgical landscape. These findings highlight critical opportunities to improve surgical outcomes: enhancing initial resection completeness and optimizing adjuvant therapies to mitigate recurrence. Ultimately, reducing reoperation rates would alleviate patient morbidity and health care expenditures, emphasizing the need for integrated, specialty-specific strategies.